Quantum Biopharma Ltd. (NASDAQ:QNTM) Sees Large Increase in Short Interest

Quantum Biopharma Ltd. (NASDAQ:QNTM) was the recipient of a large growth in short interest in the month of March. As of March 13th, there was short interest totaling 229,208 shares, a growth of 174.3% from the February 26th total of 83,550 shares. Currently, 6.6% of the shares of the company are sold short. Based on an average trading volume of 483,399 shares, the days-to-cover ratio is currently 0.5 days. Based on an average trading volume of 483,399 shares, the days-to-cover ratio is currently 0.5 days. Currently, 6.6% of the shares of the company are sold short.

Analyst Ratings Changes

QNTM has been the subject of a number of recent analyst reports. Wall Street Zen cut shares of Quantum Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, January 24th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Quantum Biopharma in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Quantum Biopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new stake in Quantum Biopharma in the 4th quarter valued at $80,000. Virtu Financial LLC bought a new stake in shares of Quantum Biopharma in the 4th quarter worth about $76,000. Finally, Steward Partners Investment Advisory LLC acquired a new stake in shares of Quantum Biopharma during the 2nd quarter worth about $63,000. 1.24% of the stock is currently owned by institutional investors.

Quantum Biopharma Price Performance

Shares of Quantum Biopharma stock opened at $4.73 on Wednesday. The company has a market cap of $18.07 million, a PE ratio of -0.43 and a beta of 0.32. The firm has a fifty day moving average price of $4.13 and a two-hundred day moving average price of $8.98. Quantum Biopharma has a fifty-two week low of $2.07 and a fifty-two week high of $38.25.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.